Levels of soluble endothelial protein C receptor are associated with CD4 + changes in maraviroc-treated HIV-infected patients

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Nozza, Silvia ^a   Pogliaghi, Manuela ^a   Chiappetta, Stefania ^a   Spagnuolo, Vincenzo ^a   Fontana, Gessica ^b   Razzari, Cristina ^b   Tambussi, Giuseppe ^a   Faioni, Elena Maria ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; D DIMER; ENDOTHELIAL PROTEIN C RECEPTOR; INTERLEUKIN 6; MARAVIROC; THROMBOMODULIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; LEUKOCYTE ANTIGEN; PROCR PROTEIN, HUMAN; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MAJOR CLINICAL STUDY; MALE; BLOOD; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD COAGULATION; CCR5 RECEPTOR ANTAGONISTS; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; TRIAZOLES;

EID: 84862009198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037032     Document Type: Article

References (21)

1. Ho JE, Hsue PY, (2009) Cardiovascular manifestations of HIV infection. Heart. 95: 1193-1202.
2. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 201: 1788-1795.
3. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, et al. (2006) Endothelial Function in HIV-Infected Persons Clinical Infectious Diseases. 42: 1325-32.
4. Kline ER, Kleinhenz DJ, Liang B, Dikalov S, Guidot DM, et al. (2008) Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration Am J Physiol Heart Circ Physiol. 294: H2792-H2804.
5. Kaplan R, Kingsley L, Gange S, Benning L, Jacobson LP, et al. (2008) Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 22: 1615-1624.
6. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. PLoS Medicine. 5: e203.
7. Calmy A, le Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, et al. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 23: 929-939.
8. Esmon CT, (2006) Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 32: 49-60.
9. Esmon CT, Gu JM, Xu J, Qu D, Stearns-Kurosawa DJ, et al. (1999) Regulation and functions of the protein C anticoagulant pathway. Haematologica. 84: 363-368.
10. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, et al. (1998) Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood. 91: 725-727.
11. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, et al. (2010) Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 201: 803-13.
12. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, et al. (2008) Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. N Engl J Med. 359: 1429-1441.
13. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, et al. (2010) Effects of Maraviroc and Efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-Infected Patients. PLoS One. 5: e13188.
14. Faioni EM, Ferrero S, Fontana G, Granelli U, Ciullo MM, et al. (2004) Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med 32(5 Suppl)pp. S266-70.
15. MacInnes A, Lazzarin A, Di Perri G, Sierra-Madero JC, Aberg J, et al. (2011) Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials. 12: 24-36.
16. Gu JM, Katsuura Y, Ferrell GL, Grammes P, Esmon CT, (2000) Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood. 95: 1687-1693.
17. Wilkin T, Lalama C, Tenorio A, Landay A, Ribaudo H, et al. (2010) Maraviroc Intensification for Suboptimal CD4+ Cell Response Despite Sustained Virologic Suppression: ACTG 5256. 17th Conference on Retrovirus and Opportunistic Infections, San Francisco, 16-19 Feb Abs 285.
18. Nixon DE, Landayb A, (2010) Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 5: 498-503.
19. Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, et al. (2005) EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis.183: 283-92.
20. Montes R, Hurtado V, Alonso A, Foco L, Zonzin P, et al. (2005) Autoantibodies against the endothelial receptor of protein C are associated with acute myocardial infarction in young women. J Thromb Haemost. 3: 1454-8.
21. MacInnes A, Lazzarin A, Di Perri G, Sierra-Madero JG, Aberg J, et al. (2011) Maraviroc can improbe lipid profiles in dysplipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials 12 (1): 24-36.